Literature DB >> 11316157

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.

C N Bernstein1, J F Blanchard, P Rawsthorne, N Yu.   

Abstract

OBJECTIVE: The aim of this study was to determine the prevalence of the major extraintestinal manifestations of inflammatory bowel disease (IBD) and their relation to disease diagnosis and gender.
METHODS: We used the population-based University of Manitoba IBD Database, which includes longitudinal files on all subjects of all health system contacts identified by International Classification of Diseases, 9th Revision, Clinical Modification codes for visit diagnosis. We extracted a cohort from our database, which included subjects with a known diagnosis of IBD for at least 10 yr. We then determined how many contacts each subject had for each of the following extraintestinal IBD-associated immune diseases: primary sclerosing cholangitis, ankylosing spondylitis, iritis/uveitis, pyoderma gangrenosum, and erythema nodosum. We calculated the prevalence of the extraintestinal diseases using an administrative definition of having at least five health system contacts for the diagnosis in question. This administrative definition has previously been validated in Crohn's disease and ulcerative colitis (UC).
RESULTS: A total of 6.2% of patients with IBD had one of six major extraintestinal diseases studied in this report. Only 0.3% of patients had multiple extraintestinal diseases. Iritis/uveitis was the most common extraintestinal disease of all assessed (2.2% of women and 1.1% of men). Iritis/uveitis was more common among women, particularly those with UC (3.8%). Primary sclerosing cholangitis was most common among men with UC (3%). Ankylosing spondylitis was more common among men, and the highest rate was seen among men with Crohn's disease (2.7%). Pyoderma gangrenosum was more common in Crohn's (1.2%) with no gender predilection. Erythema nodosum was similarly present in Crohn's and UC but was more common among women (1.9%).
CONCLUSIONS: The associations of immune mediated diseases in extraintestinal sites may help us to further our understanding of IBD pathogenesis, and it may help us in developing a paradigm of disease subsets.

Entities:  

Mesh:

Year:  2001        PMID: 11316157     DOI: 10.1111/j.1572-0241.2001.03756.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  189 in total

Review 1.  MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.

Authors:  Lily P H Yang; Paul L McCormack
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

3.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

4.  Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.

Authors:  Gaurav Arora; Gurkirpal Singh; Shweta Vadhavkar; Shamita B Shah; Ajitha Mannalithara; Alka Mithal; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

5.  Sacroiliitis is common in Crohn's disease patients with perianal or upper gastrointestinal involvement.

Authors:  Young Hwangbo; Hyo Jong Kim; Ji Seon Park; Kyung Nam Ryu; Nam Hoon Kim; Jaejun Shim; Jae Young Jang; Seok Ho Dong; Byung Ho Kim; Young Woon Chang; Rin Chang
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

6.  Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.

Authors:  Sasha Taleban; Dalin Li; Stephan R Targan; Andrew Ippoliti; Steven R Brant; Judy H Cho; Richard H Duerr; John D Rioux; Mark S Silverberg; Eric A Vasiliauskas; Jerome I Rotter; Talin Haritunians; David Q Shih; Marla Dubinsky; Gil Y Melmed; Dermot P B McGovern
Journal:  J Crohns Colitis       Date:  2015-10-08       Impact factor: 9.071

7.  Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Authors:  M Severs; S J H van Erp; M E van der Valk; M J J Mangen; H H Fidder; M van der Have; A A van Bodegraven; D J de Jong; C J van der Woude; M J L Romberg-Camps; C H M Clemens; J M Jansen; P C van de Meeberg; N Mahmmod; C Y Ponsioen; C Bolwerk; J R Vermeijden; M J Pierik; P D Siersema; M Leenders; A E van der Meulen-de Jong; G Dijkstra; B Oldenburg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

8.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Compromised neuroimmune status in rats with experimental colitis.

Authors:  Lysa Boissé; Marja D Van Sickle; Keith A Sharkey; Quentin J Pittman
Journal:  J Physiol       Date:  2003-03-14       Impact factor: 5.182

10.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.